drugset
drugset / Trial / NCT06953843

Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases

NCT06953843 ↗

Phase 2 Recruiting 366 enrolled Xinqiao Hospital of Chongqing
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aims to conduct a prospective, multicenter, umbrella clinical study to compare the abscopal effects of different radiotherapy fractionation patterns combined with Benmelstobart, and to explore an efficient and low-toxic treatment strategy for non-small cell lung cancer (NSCLC) with multiple metastases. The main objective is to explore and compare the control rates of abscopal lesions in NSCLC patients with multiple metastases when different radiotherapy fractionation patterns are combined with Benmelstobart.

Timeline

Start
2025-07-09
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Benmelstobart Monoclonal antibody — —
Subject Bevacizumab Monoclonal antibody — —

Indications

No indication recorded.